Iisrael - heebrea - Ministry of Health

neopharm ltd, israel - sodium chloride - תמיסה - sodium chloride 9 g/l

Iisrael - heebrea - Ministry of Health

neopharm (israel) 1996 ltd - calcium chloride dihydrate; potassium chloride; sodium chloride; sodium lactate - תמיסה לאינפוזיה - sodium lactate 3.17 g / 1 l; calcium chloride dihydrate 0.27 g / 1 l; potassium chloride 0.4 g / 1 l; sodium chloride 6 g / 1 l - electrolytes

Iisrael - heebrea - Ministry of Health

neopharm (israel) 1996 ltd - calcium chloride dihydrate; potassium chloride; sodium chloride; sodium lactate - תמיסה לאינפוזיה - sodium lactate 3.17 g / 1 l; calcium chloride dihydrate 0.27 g / 1 l; potassium chloride 0.4 g / 1 l; sodium chloride 6 g / 1 l - electrolytes

Iisrael - heebrea - Ministry of Health

neopharm consumer products ltd, israel - polyethylene glycol 3350 - אבקה להכנת תרחיף - polyethylene glycol 3350 99.973 %w/w - macrogol - macrogol - treatment of constipation.

Iisrael - heebrea - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Iisrael - heebrea - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Iisrael - heebrea - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Iisrael - heebrea - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Iisrael - heebrea - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Iisrael - heebrea - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.